Summit Therapeutics PLC (SMMT) Given Daily Media Sentiment Rating of 0.13
News coverage about Summit Therapeutics PLC (NASDAQ:SMMT) has trended somewhat positive recently, according to Accern. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Summit Therapeutics PLC earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.0038244859722 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Several brokerages recently commented on SMMT. Oppenheimer Holdings, Inc. reissued a “buy” rating and set a $24.00 target price on shares of Summit Therapeutics PLC in a report on Monday, October 16th. Canaccord Genuity reissued a “buy” rating on shares of Summit Therapeutics PLC in a report on Monday, October 16th. ValuEngine cut Summit Therapeutics PLC from a “hold” rating to a “sell” rating in a report on Thursday, October 5th. Finally, Zacks Investment Research cut Summit Therapeutics PLC from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Two investment analysts have rated the stock with a sell rating and three have given a buy rating to the company’s stock. Summit Therapeutics PLC currently has a consensus rating of “Hold” and a consensus target price of $23.50.
Summit Therapeutics PLC (NASDAQ SMMT) traded up $0.35 during midday trading on Monday, hitting $9.40. The company’s stock had a trading volume of 64,784 shares, compared to its average volume of 31,374. Summit Therapeutics PLC has a 52 week low of $7.95 and a 52 week high of $16.86.
Summit Therapeutics PLC (NASDAQ:SMMT) last posted its quarterly earnings results on Thursday, August 31st. The company reported $1.10 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.38 by ($0.28). The company had revenue of $25.01 million during the quarter, compared to the consensus estimate of $31.37 million. Summit Therapeutics PLC had a negative net margin of 12.44% and a negative return on equity of 29,334.40%. equities research analysts forecast that Summit Therapeutics PLC will post -0.5 EPS for the current fiscal year.
Summit Therapeutics PLC Company Profile
Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Receive News & Stock Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related stocks with our FREE daily email newsletter.